Pascetti Erica, Floren Muskan, Fernandes Tatiane da Silva, Anastasio Carina, Doyle Levi, Gillette Jennifer
Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131.
University of New Mexico Comprehensive Cancer Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131.
Mol Biol Cell. 2025 Jul 1;36(7):br19. doi: 10.1091/mbc.E24-10-0474. Epub 2025 May 28.
The cellular demand of the hematopoietic system is maintained by a rare pool of tissue-specific, hematopoietic stem cells (HSC). HSCs are primarily maintained in a quiescent state but can be activated to exit quiescence and undergo self-renewal and differentiation in response to stress. The cytokine transforming growth factor-β (TGF-β) plays an essential role in supporting HSC quiescence and activation, as one of the most potent inhibitors of hematopoietic stem and progenitor cell (HSPC) growth. Therefore, how TGF-β signaling can be regulated in the context of HSCs is of significant interest as it may uncover novel mechanisms to target HSC activity. Previous studies revealed that the tetraspanin CD82 modulates the long-term HSC population, with CD82 knockout (KO) mice displaying increased HSC activation. Here, in this study, we connect the CD82 scaffold with the regulation of TGF-β signaling in HSPCs. We show that CD82KO leads to decreased TGF-β signaling, whereas increased CD82 expression promotes TGF-β activation. These changes in CD82-mediated TGF-β signaling are associated with extracellular matrix interactions, as fibronectin engagement is critical for promoting TGF-β signaling. Mechanistically, we find that CD82 stimulates enhanced TGF-β activation by promoting receptor cross-talk between TGF-β receptor I and integrin β1, resulting in downstream changes in cell proliferation. Collectively, these findings demonstrate that CD82 modulates canonical TGF-β signaling through receptor cross-talk mechanisms that may be targeted to alter the balance between HSC quiescence and activation.
造血系统的细胞需求由一组罕见的组织特异性造血干细胞(HSC)维持。造血干细胞主要维持在静止状态,但在应激反应下可被激活,从而退出静止状态并进行自我更新和分化。细胞因子转化生长因子-β(TGF-β)作为造血干细胞和祖细胞(HSPC)生长的最有效抑制剂之一,在支持造血干细胞的静止和激活方面发挥着重要作用。因此,在造血干细胞的背景下,TGF-β信号如何被调节备受关注,因为这可能揭示靶向造血干细胞活性的新机制。先前的研究表明,四跨膜蛋白CD82调节长期造血干细胞群体,CD82基因敲除(KO)小鼠表现出造血干细胞激活增加。在此研究中,我们将CD82支架与造血干细胞中TGF-β信号的调节联系起来。我们发现CD82基因敲除导致TGF-β信号减弱,而CD82表达增加则促进TGF-β激活。CD82介导的TGF-β信号的这些变化与细胞外基质相互作用有关,因为纤连蛋白的结合对于促进TGF-β信号至关重要。从机制上讲,我们发现CD82通过促进TGF-β受体I和整合素β1之间的受体串扰来刺激增强的TGF-β激活,从而导致细胞增殖的下游变化。总的来说,这些发现表明CD82通过受体串扰机制调节经典的TGF-β信号,这可能是靶向改变造血干细胞静止和激活之间平衡的靶点。